Research and progress on biomarkers of neuromyelitis optica spectrum disorders

References

• Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler. 2015;21(7):845–853.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS. Mult Scler. 2011;17(11):1384–1386.
   PubMed Web of Science ®Google Scholar
• Devic C. Myelite subaigue compliquee de nevrite optique. Bull Med. 1894;35:18–30.
   Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–2112.
   PubMed Web of Science ®Google Scholar
• Jarius S, Franciotta D, Paul F, et al. Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci. 2012;320(1–2):32–37.
   PubMed Web of Science ®Google Scholar
• Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8:184.
   PubMed Web of Science ®Google Scholar
• Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79(12):1273–1277.
   PubMed Web of Science ®Google Scholar
• Rostásy K, Mader S, Hennes EM, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler. 2013;19(8):1052–1059.
   PubMed Web of Science ®Google Scholar
• Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76(3):301–309.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189.
   PubMed Web of Science ®Google Scholar
• Ikeshima-Kataoka H. Neuroimmunological Implications of AQP4 in Astrocytes. Int J Mol Sci. 2016;17(8):1306.
   Web of Science ®Google Scholar
• Vaknin-Dembinsky A, Karussis D, Avichzer J, et al. NMO spectrum of disorders: a paradigm for astrocyte-targeting autoimmunity and its implications for MS and other CNS inflammatory diseases. J Autoimmun. 2014;54:93–99.
   PubMed Web of Science ®Google Scholar
• Verkman AS, Phuan PW, Asavapanumas N, et al. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol. 2013;23(6):684–695.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Lim YM, Kim S, et al. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. Ann Clin Transl Neurol. 2020;7(6):992–1001.
   PubMed Web of Science ®Google Scholar
• Brenner M, Johnson AB, Boespflug-Tanguy O, et al. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet. 2001;27(1):117–120.
   PubMed Web of Science ®Google Scholar
• Misu T, Takano R, Fujihara K, et al. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry. 2009;80(5):575–577.
   PubMed Web of Science ®Google Scholar
• Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2010;75(3):208–216.
   PubMed Web of Science ®Google Scholar
• Kaneko K, Sato DK, Nakashima I, et al. CSF cytokine profile in MOG-IgG + neurological disease is similar to AQP4-IgG + NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry. 2018;89(9):927–936.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019;93(13):e1299–e1311.
   PubMed Web of Science ®Google Scholar
• Abdelhak A, Huss A, Kassubek J, et al. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8(1):14798.
   PubMedGoogle Scholar
• Donato R. Perspectives in S-100 protein biology. Review article. Cell Calcium. 1991;12(10):713–726.
   PubMed Web of Science ®Google Scholar
• Pozdnyakov N, Margulis A, Sitaramayya A. Identification of effector binding sites on S100 beta: studies with guanylate cyclase and p80, a retinal phosphoprotein. Biochemistry. 1998;37(30):10701–10708.
   PubMed Web of Science ®Google Scholar
• Ziegler DR, Innocente CE, Leal RB, et al. The S100B protein inhibits phosphorylation of GFAP and vimentin in a cytoskeletal fraction from immature rat hippocampus. Neurochem Res. 1998;23(10):1259–1263.
   PubMed Web of Science ®Google Scholar
• Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33(7):637–668.
   PubMed Web of Science ®Google Scholar
• Zimmer DB, Van Eldik LJ. Analysis of the calcium-modulated proteins, S100 and calmodulin, and their target proteins during C6 glioma cell differentiation. J Cell Biol. 1989;108(1):141–151.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Changyaleket B, Xu H, et al. Identifying S100B as a biomarker and a therapeutic target for brain injury and multiple diseases. Curr Med Chem. 2016;23(15):1571–1596.
   PubMed Web of Science ®Google Scholar
• Ye H, Wang L, Yang XK, et al. Serum S100B levels may be associated with cerebral infarction: a meta-analysis. J Neurol Sci. 2015;348(1–2):81–88.
   PubMed Web of Science ®Google Scholar
• Allouchery G, Moustafa F, Roubin J, et al. Clinical validation of S100B in the management of a mild traumatic brain injury: issues from an interventional cohort of 1449 adult patients. Clin Chem Lab Med. 2018;56(11):1897–1904.
   PubMed Web of Science ®Google Scholar
• Cristóvão JS, Morris VK, Cardoso I, et al. The neuronal S100B protein is a calcium-tuned suppressor of amyloid-β aggregation. Sci Adv. 2018;4(6):eaaq1702.
   PubMed Web of Science ®Google Scholar
• Shashoua VE, Hesse GW, Moore BW. Proteins of the brain extracellular fluid: evidence for release of S-100 protein. J Neurochem. 1984;42(6):1536–1541.
   PubMed Web of Science ®Google Scholar
• Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol. 1994;4(3):229–237.
   PubMed Web of Science ®Google Scholar
• Petzold A, Keir G, Lim D, et al. Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern. Brain Res Bull. 2003;61(3):281–285.
   PubMed Web of Science ®Google Scholar
• Kapural M, Krizanac-Bengez L, Barnett G, et al. Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Res. 2002;940(1–2):102–104.
   PubMed Web of Science ®Google Scholar
• Huttunen HJ, Kuja-Panula J, Sorci G, et al. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem. 2000;275(51):40096–40105.
   PubMed Web of Science ®Google Scholar
• Hu J, Castets F, Guevara JL, et al. Van Eldik LJ. S100 beta stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J Biol Chem. 1996;271(5):2543–2547.
   PubMed Web of Science ®Google Scholar
• Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain? J Neurosci Res. 2007;85(7):1373–1380.
   PubMed Web of Science ®Google Scholar
• Michetti F, Massaro A, Murazio M. The nervous system-specific S-100 antigen in cerebrospinal fluid of multiple sclerosis patients. Neurosci Lett. 1979;11(2):171–175.
   PubMed Web of Science ®Google Scholar
• Massaro AR, Michetti F, Laudisio A, et al. Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase. Ital J Neurol Sci. 1985;6(1):53–56.
   PubMedGoogle Scholar
• Fujii C, Tokuda T, Ishigami N, et al. Usefulness of serum S100B as a marker for the acute phase of aquaporin-4 autoimmune syndrome. Neurosci Lett. 2011;494(1):86–88.
   PubMed Web of Science ®Google Scholar
• Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577–589.
   PubMed Web of Science ®Google Scholar
• Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75(1):116–126.
   PubMed Web of Science ®Google Scholar
• Mattsson N, Andreasson U, Zetterberg H, et al. Alzheimer’s disease neuroimaging initiative. association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557–566.
   PubMed Web of Science ®Google Scholar
• Weydt P, Oeckl P, Huss A, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016;79 (1):152–158.
   PubMed Web of Science ®Google Scholar
• Lycke JN, Karlsson JE, Andersen O, et al. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64(3):402–404.
   PubMed Web of Science ®Google Scholar
• Rohrer JD, Woollacott IO, Dick KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329–1336.
   PubMed Web of Science ®Google Scholar
• Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857–870.
   PubMed Web of Science ®Google Scholar
• Deisenhammer F, Zetterberg H, Fitzner B, et al. The cerebrospinal fluid in multiple sclerosis. Front Immunol. 2019;10:726.
   PubMedGoogle Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473–477.
   PubMed Web of Science ®Google Scholar
• Linhares UC, Schiavoni PB, Barros PO, et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol. 2013;33(1):179–189.
   PubMed Web of Science ®Google Scholar
• Agasing AM, Wu Q, Khatri B, et al. Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nat Commun. 2020;11(1):2856.
   PubMed Web of Science ®Google Scholar
• Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA. 2011;108(9):3701–3706.
   PubMed Web of Science ®Google Scholar
• Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302–1306.
   PubMed Web of Science ®Google Scholar
• Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310–1315.
   PubMed Web of Science ®Google Scholar
• Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome. J Clin Invest. 2002;109(1):59–68.
   PubMed Web of Science ®Google Scholar
• Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci. 2005;1050(1):34–39.
   PubMedGoogle Scholar
• Yandamuri SS, Jiang R, Sharma A, et al. High-throughput investigation of molecular and cellular biomarkers in NMOSD. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e852.
   PubMed Web of Science ®Google Scholar
• Ratelade J, Asavapanumas N, Ritchie AM, et al. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol. 2013;126(5):699–709.
   PubMed Web of Science ®Google Scholar
• Hakobyan S, Luppe S, Evans DR, et al. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Mult Scler. 2017;23(7):946–955.
   PubMed Web of Science ®Google Scholar
• Zelek WM, Fathalla D, Morgan A, et al. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Mult Scler. 2019. DOI:https://doi.org/10.1177/1352458519887905
   Google Scholar
• Ding J, Zhu DS, Hong RH, et al. The differential expression of natural killer cells in NMOSD and MS. J Clin Neurosci. 2020;71:9–14.
   PubMed Web of Science ®Google Scholar
• Duan T, Smith AJ, Verkman AS. Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity. Acta Neuropathol Commun. 2019;7(1):112.
   PubMedGoogle Scholar
• Lanier LL, Le AM, Civin CI, et al. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986;136(12):4480–4486.
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Guo Y, Popescu BF, et al. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014;24(1):83–97.
   PubMed Web of Science ®Google Scholar
• Chen T, Lennon VA, Liu YU, et al. Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion. J Clin Invest. 2020;130(8):4025–4038.
   PubMed Web of Science ®Google Scholar
• Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2016;53(2):1181–1194.
   PubMed Web of Science ®Google Scholar
• Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell. 2017;169(7):1276–1290.
   PubMed Web of Science ®Google Scholar
• Lecca D, Janda E, Mulas G, et al. Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson’s disease models. Br J Pharmacol. 2018;175(16):3298–3314.
   PubMed Web of Science ®Google Scholar
• Boillée S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389–1392.
   PubMed Web of Science ®Google Scholar
• Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164(10):4991–4995.
   PubMed Web of Science ®Google Scholar
• Zhong L, Chen XF, Wang T, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med. 2017;214(3):597–607.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201(4):647–657.
   PubMed Web of Science ®Google Scholar
• Piccio L, Buonsanti C, Mariani M, et al. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol. 2007;37(5):1290–1301.
   PubMed Web of Science ®Google Scholar
• Suárez-Calvet M, Araque Caballero MÁ, Kleinberger G, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8(369):369ra178.
   PubMed Web of Science ®Google Scholar
• Öhrfelt A, Axelsson M, Malmeström C, et al. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Mult Scler. 2016;22(12):1587–1595.
   PubMed Web of Science ®Google Scholar
• Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385(6617):640–644.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Imaizumi T, Fujimoto K, et al. Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes. Neurosci Lett. 2001;303(2):132–136.
   PubMed Web of Science ®Google Scholar
• Chapman GA, Moores K, Harrison D, et al. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci. 2000;20(15):RC87.
   PubMed Web of Science ®Google Scholar
• Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA. 1998;95(18):10896–10901.
   PubMed Web of Science ®Google Scholar
• Lyons A, Lynch AM, Downer EJ, et al. Fractalkine-induced activation of the phosphatidylinositol-3 kinase pathway attentuates microglial activation in vivo and in vitro. J Neurochem. 2009;110(5):1547–1556.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Kawanokuchi J, Numata K, et al. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 2003;979(1–2):65–70.
   PubMed Web of Science ®Google Scholar
• Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333(6048):1456–1458.
   PubMed Web of Science ®Google Scholar
• Maciejewski-Lenoir D, Chen S, Feng L, et al. Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J Immunol. 1999;163(3):1628–1635.
   PubMed Web of Science ®Google Scholar
• Pabon MM, Bachstetter AD, Hudson CE, et al. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson’s disease. J Neuroinflammation. 2011;8:9.
   PubMed Web of Science ®Google Scholar
• Zujovic V, Benavides J, Vigé X, et al. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia. 2000;29(4):305–315.
   PubMed Web of Science ®Google Scholar
• Sunnemark D, Eltayeb S, Nilsson M, et al. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflammation. 2005;2:17.
   PubMed Web of Science ®Google Scholar